RxDoctor Payments Data

Kyle Heron, MD

Pain Medicine · Modesto, CANPI 1912918962

Payments from drug & device makers

$8,417in general payments, 2019–2025

Across 205 payments — averaging $41.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Relievant Medsystems, Inc.$673
  • Painteq LLC$605
  • Foundation Fusion Solutions, LLC$371
  • Stryker$316
  • Electronic Waveform Lab, Inc.$223
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$2,10525%
  • Food & beverage$6,26974%
  • Education$441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,417 in reported general payments places this provider in the 75th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$261,242
Medicare patients
461
Services billed
2,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl90$132,588
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,350$46,813
PercocetOxycodone Hcl/Acetaminophen13$41,995
Xtampza ErOxycodone Myristate40$37,409
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen480$26,329
MovantikNaloxegol Oxalate62$26,010
Fentanyl151$25,275
Oxycodone Hcl430$17,952
RoxicodoneOxycodone Hcl12$17,806
BelbucaBuprenorphine Hcl13$12,744
Morphine Sulfate ErMorphine Sulfate275$12,574
Methadone Hcl314$6,942
XanaxAlprazolam11$6,537
Tizanidine Hcl288$4,392
Acetaminophen-CodeineAcetaminophen With Codeine77$3,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$139$50,15353 claims
Redhill Biopharma Inc.Movantik$19$26,01062 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 pain medicine providers in California.

Other pain medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →